Columnists
Tipsheet
Cartoons
Podcasts
Newsletters
Sections
Podcasts
Townhall TV
Election
Capitol Voices
Entertainment
Radio News
Live Blog
Topics
Sites
Hot Air
PJ Media
Bearing Arms
Twitchy
RedState
JOIN VIP
LOGIN
MY ACCOUNT
Account Settings
Newsletter Subscriptions
Log Out
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Aprea Therapeutics Inc
(NQ:
APRE
)
4.000
UNCHANGED
Streaming Delayed Price
Updated: 2:18 PM EDT, Jul 19, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
1,617
Open
4.000
Bid (Size)
3.720 (25)
Ask (Size)
4.100 (10)
Prev. Close
4.000
Today's Range
3.990 - 4.000
52wk Range
2.830 - 8.847
Shares Outstanding
5,430,215
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Aprea Therapeutics to Host Virtual KOL Event on APR-1051, a Highly Selective and Potentially Best-in-Class Oral WEE1 Inhibitor, on Monday, June 24, 2024
June 21, 2024
Webinar will include discussion of APR-1051 in context of emerging WEE1 inhibitor landscape
From
Aprea Therapeutics
Via
GlobeNewswire
Aprea Therapeutics Announces First Patient Dosed in ACESOT-1051 Phase 1 Trial Evaluating Oral WEE1 Inhibitor APR-1051
June 17, 2024
From
Aprea Therapeutics
Via
GlobeNewswire
Performance
YTD
-20.00%
-20.00%
1 Month
-1.72%
-1.72%
3 Month
-25.23%
-25.23%
6 Month
-25.79%
-25.79%
1 Year
+16.96%
+16.96%
More News
Read More
Aprea Therapeutics Announces that Safety Review Committee (SRC) Endorses Dosing of Patients with ATRN-119 at 800 mg Once Daily in Ongoing ABOYA-119 Clinical Trial
May 28, 2024
From
Aprea Therapeutics
Via
GlobeNewswire
Aprea Therapeutics: Q4 Earnings Insights
March 26, 2024
Via
Benzinga
APRE Stock Earnings: Aprea Therapeutics Beats EPS for Q1 2024
May 14, 2024
Via
InvestorPlace
Aprea Therapeutics Reports First quarter 2024 Financial Results and Provides a Business Update
May 14, 2024
From
Aprea Therapeutics
Via
GlobeNewswire
Aprea Therapeutics to Attend the 2024 RBC Capital Markets Global Healthcare Conference
May 13, 2024
From
Aprea Therapeutics
Via
GlobeNewswire
Aprea Therapeutics Announces Appointment of Nadeem Q. Mirza, M.D., M.P.H. as Chief Medical Officer and Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
May 02, 2024
From
Aprea Therapeutics
Via
GlobeNewswire
Aprea Therapeutics Announces Presentations on its Next Generation WEE1 Inhibitor, APR-1051, and A Novel Macrocyclic ATR Inhibitor, ATRN-119, at AACR Annual Meeting 2024
April 10, 2024
From
Aprea Therapeutics
Via
GlobeNewswire
12 Health Care Stocks Moving In Thursday's Pre-Market Session
April 04, 2024
Via
Benzinga
APRE Stock Earnings: Aprea Therapeutics Misses EPS, Misses Revenue for Q4 2023
March 26, 2024
Via
InvestorPlace
Aprea Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Business Update
March 26, 2024
From
Aprea Therapeutics
Via
GlobeNewswire
Why Is Precision Oncology-Focused Aprea Therapeutics Stock Trading Higher On Monday?
March 11, 2024
Via
Benzinga
Exposures
Product Safety
12 Health Care Stocks Moving In Monday's Pre-Market Session
March 11, 2024
Via
Benzinga
Aprea Therapeutics Announces Private Placement Financing of up to $34.0 Million
March 11, 2024
From
Aprea Therapeutics
Via
GlobeNewswire
Aprea Therapeutics Announces FDA Clearance of IND for APR-1051, its Next Generation WEE1 Kinase Inhibitor for Cyclin E Overexpressing Cancers
March 11, 2024
From
Aprea Therapeutics
Via
GlobeNewswire
Aprea Therapeutics Announces Acceptance of Abstracts at American Association of Cancer Research Annual Meeting 2024
March 05, 2024
From
Aprea Therapeutics
Via
GlobeNewswire
Aprea Therapeutics Announces Submission of IND Application for APR-1051, a Next Generation WEE1 Kinase Inhibitor
February 06, 2024
From
Aprea Therapeutics
Via
GlobeNewswire
Aprea Therapeutics to Present at DDR Inhibitors Summit 2024
January 30, 2024
From
Aprea Therapeutics
Via
GlobeNewswire
Aprea Therapeutics Provides Corporate Update and Announces Development Plans for 2024
January 04, 2024
From
Aprea Therapeutics
Via
GlobeNewswire
Aprea Therapeutics Reports Third Quarter 2023 Financial Results and Provides a Business Update
November 09, 2023
From
Aprea Therapeutics
Via
GlobeNewswire
A Look Into Healthcare Sector Value Stocks
October 30, 2023
Via
Benzinga
Aprea Therapeutics to Host a Key Opinion Leader (KOL) Event on its Synthetic Lethality (SL) and DNA Damage Response (DDR) Pathways
October 24, 2023
From
Aprea Therapeutics
Via
GlobeNewswire
Aprea Unveils Initial Clinical Data on ATRi, ATRN-119, and Pre-Clinical Data on WEE1i, ATRN-1051, at AACR-NCI-EORTC International Conference Supporting Highly Differentiated Synthetic Lethality Portfolio
October 16, 2023
From
Aprea Therapeutics
Via
GlobeNewswire
5 Value Stocks To Watch In The Healthcare Sector
September 25, 2023
Via
Benzinga
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.